Trials / Unknown
UnknownNCT03815071
A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells
Clinical Study of the Safety and Efficacy of Autologous Neural Stem Cells in the Treatment of Parkinson's Disease
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Allife Medical Science and Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center, single arm and open-label study to investigate the safety and efficacy of iPS-NCS with Parkinson's Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ips-nsc cells | Total dose of ips-nsc cells will be administered at day0. |
Timeline
- Start date
- 2019-02-01
- Primary completion
- 2020-02-01
- Completion
- 2021-02-01
- First posted
- 2019-01-24
- Last updated
- 2019-01-31
Source: ClinicalTrials.gov record NCT03815071. Inclusion in this directory is not an endorsement.